AE
Publicaties op Oncologisch.com
Health-related quality of life with first- vs tweedelijns CDK4/6 inhibitor use in gevorderd breast cancer: results fr...
Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus tweedelijns for gevorderd breast cancer: ...
Ribociclib-Letrozole Combination as an Alternative for Neoadjuvant Chemotherapy in Selected Postmenopausal Patients w...
Optimale duur van verlengde adjuvante endocriene therapie: IDEAL-studie (BOOG 2006-05)